healio.com
VIDEO: Be aware of comorbidities when selecting treatment for patients with IBD
Extraintestinal issues (joints, eyes, skin, bone, kidneys, liver) are common in IBD and can influence which medications will help both gut disease and other problems. Knowing these risks affects monitoring and cancer surveillance schedules.
Clinicians treating IBD, adult patients with Crohn’s disease or ulcerative colitis, and caregivers concerned about extraintestinal manifestations and surveillance needs.
What To Know
What to know This Healio video discusses common extraintestinal manifestations and comorbidities in patients with IBD and why they matter when choosing therapies.
The speaker reviews inflammatory arthritis (peripheral and axial), uveitis/iritis and the need for ophthalmology evaluation, psoriasis and dermatologic overlap, bone loss (osteopenia/osteoporosis) and steroid-related risk, kidney stones (noting calcium oxalate stones in Crohn’s), primary sclerosing cholangitis (PSC) and its implications for liver testing and colon surveillance, and colorectal cancer surveillance timing in IBD (including yearly colonoscopy for those with PSC).
Clinicians should consider these comorbid conditions when selecting IBD treatments because some medications treat both gut inflammation and specific extraintestinal manifestations while others do not. This is a brief clinical perspective video, not new clinical-trial data or treatment guidance.
This is a short expert video commentary summarizing clinical considerations rather than presenting new research or trial results. It references guideline-based surveillance (colonoscopies, PSC-related surveillance) and common complications; viewers should consult treating clinicians for individual management and specific surveillance timing.
